Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enavogliflozin vs Pioglitazone as Add-ons to Metformin in Type 2 Diabetes
NCT06399835Phase 4Recruiting
- Sponsor
- Seoul National University Bundang Hospital
- Start
- Feb 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of enavogliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Seoul National University Bundang Hospital. Primary endpoint: Changes of HbA1c from baseline at 24 weeks. Started Feb 2024; status: recruiting.
02
Drugs
enavogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06399835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06399835.